Location of Repository

The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.

By Giuseppe Visani, Massimo Breccia, Pier Paolo Piccaluga, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, Mario Annunziata, Luigiana Luciano, Andrea Camera, Francesco Cavazzini, Fabio Stagno, Francesco Di Raimondo, Patrizia Pregno, Francesca Pirillo, Valeria Santini, Alberto Bosi, Matteo Pacilli, Ester Pungolino, Emilio Usala, Emanuele Angelucci, Monica Crugnola, Gianni Binotto, Elena Maino, Federica Loscocco, Sara Barulli, Giuseppina Nicolini, Antonio Cuneo, Roberto Latagliata and Felicetto Ferrara and Alessandro Isidori
Year: 2009
OAI identifier: oai:iris.unife.it:11392/1401585
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/11392/14... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.